Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N17350 in Advanced Solid Tumors
NCT07339176Phase 2Recruiting
- Sponsor
- Onchilles Pharma
- Start
- May 2026
- Primary completion
- Jul 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of N17350 in solid tumor, triple-negative breast cancer (TNBC), Squamous Cell Carcinoma of the Skin (SCC) and 3 more (10 arms), sponsored by Onchilles Pharma. Primary endpoints: Safety and tolerability of intratumoral N17350, including incidence of DLTs and adverse events at 4 months and Objective Response Rate at 15 months. Started May 2026; status: recruiting.
02
Drugs
N17350
03
Conditions
solid tumortriple-negative breast cancer (TNBC)Squamous Cell Carcinoma of the Skin (SCC)melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07339176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07339176.